CN Patent

CN113453684A — 用于治疗癌症的csf1r抑制剂

Assigned to Deciphera Pharmaceuticals LLC · Expires 2021-09-28 · 5y expired

What this patent protects

本文描述了用于治疗癌症及与肿瘤相关巨噬细胞(TAM)的增殖减少、耗竭或再极化有关的其他肿瘤的方法及治疗相关病症(包括腱鞘巨细胞瘤(TGCT)及弥漫型腱鞘巨细胞瘤(DTGCT))的CSF1R抑制剂。

USPTO Abstract

本文描述了用于治疗癌症及与肿瘤相关巨噬细胞(TAM)的增殖减少、耗竭或再极化有关的其他肿瘤的方法及治疗相关病症(包括腱鞘巨细胞瘤(TGCT)及弥漫型腱鞘巨细胞瘤(DTGCT))的CSF1R抑制剂。

Drugs covered by this patent

Romvimza (VIMSELTINIB) · Deciphera Pharms

Patent Metadata

Patent number: CN113453684A
Jurisdiction: CN
Classification: —
Expires: 2021-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.